ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing

ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

J&J Adjusts Dosing Strategy for Actinium Prostate Cancer Drug Following Early Study Setbacks

J&J, Johnson & Johnson, actinium prostate cancer drug, capped dosing, flexible dosing, patient deaths, early study, clinical trial, cancer treatment, drug development.